Active surveillance of adverse events after immunization (AEFI) from the Local Health Unit of Ferrara, Italy


Vaccination; adverse events after immunization; surveillance system; vaccine vigilance


Vaccine vigilance implies the collection, evaluation, analysis and communication of adverse events following immunization (AEFI) and is a useful tool for vaccine monitoring allowing, even after approval and marketing, to check its safety/tolerability. The multiregional project "Active surveillance of adverse vaccine reactions", joined by the AUSL of Ferrara, is aimed at making parents of children, who have undergone at least one vaccination provided by the regional vaccination calendar in the first 24 months of life, aware of the reporting of any AEFI via mobile phone-SMS.
An analysis of the project data, collected in the period March 2018 - May 2019, was carried out, to evaluate the effectiveness of the reporting tool and the type and frequency of AEFI. Anonymized data were analyzed by number, gender, distribution by age, type of vaccine, adverse event, severity and outcome.
A total of 1494 consents and 983 SMS messages were obtained from parents.
The vaccine doses carried out were 1,984 (28.3% hexavalent, 28% PCV13, 17% anti-rotavirus, 14.3% Men-B). Almost all (99.5%) AEFI were classified as "not serious".
Based on the Organ System Class (SOC), most reports are related to "General Disorders and Administration Site Conditions" (52.3%), followed by "Psychiatric Disorders" (26.5%) and "Metabolic and nutrition disorders" (12.5%).
The reported AEFI are in line with the ones reported in the literature.
Reporting via SMS is a valid vaccine surveillance tool contributing to the qualitative and quantitative improvement of the information transmitted.


[1] Decreto legge 7 giugno 2017, n. 73, Disposizioni urgenti in materia di prevenzione vaccinale, modificato dalla Legge di conversione 31 luglio 2017, n. 119.
[2] Agenzia Italiana del Farmaco (AIFA). Rapporto vaccini 2018 – Sorveglianza post marketing in Italia. Available at: Accessed on 20/06/2020.
[3] WHO. Causality assessment of an adverse event following immunization (AEFI). User manual for the revised classification (second edition). Available at:;jsessionid=697D60B13988EB4549AEC1E3876016DC?sequence=1. Accessed on 18/06/2020.
[4] WHO. Global Vaccine Safety. Adverse event following immunization. Available at: Accessed on 18/06/2020.
[5] Agenzia Italiana del Farmaco (AIFA). La vaccinovigilanza in Italia: ruolo e obiettivi. Available at: Accessed on 20/06/2020.
[6] Bollaerts K, De Smedt T, Donegan K, Titievsky L, Bauchau V. Benefit–Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project. Drug Saf 2018; 41, 775–786.
[7] Westphal DW, Williams SA, Leeb A, Effler PV. Continuous active surveillance of adverse events following immunisation using SMS technology. Vaccine 2016; 34(29):3350-3355. doi:10.1016/j.vaccine.2016.05.015
[8] Scavone C, Rafaniello C, Brusco S, Bertini M, Menditto E, Orlando V, Trama U, Sportiello L, Rossi F, Capuano A. Did the New Italian Law on Mandatory Vaccines Affect Adverse Event Following Immunization's Reporting? A Pharmacovigilance Study in Southern Italy. Front. Pharmacol. 2018; 9:1003. doi: 10.3389/fphar.2018.01003.
[9] Pillsbury A, Quinn H, Cashman P, Leeb A, Macartney K; AusVaxSafety consortium. Active SMS-based influenza vaccine safety surveillance in Australian children. Vaccine 2017; 35(51):7101-7106. doi:10.1016/j.vaccine.2017.10.091.
[10] Regan AK, Blyth CC, Tracey L, Mak DB, Richmond PC, Effler PV. Comparison of text-messaging to voice telephone interviews for active surveillance of adverse events following immunisation. Vaccine 2015; 33(31):3689-3694. doi:10.1016/j.vaccine.2015.06.022.